학술논문
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Document Type
article
Author
Rajasekharan Somasundaram; Thomas Connelly; Robin Choi; Hyeree Choi; Anastasia Samarkina; Ling Li; Elizabeth Gregorio; Yeqing Chen; Rohit Thakur; Mohamed Abdel-Mohsen; Marilda Beqiri; Meaghan Kiernan; Michela Perego; Fang Wang; Min Xiao; Patricia Brafford; Xue Yang; Xiaowei Xu; Anthony Secreto; Gwenn Danet-Desnoyers; Daniel Traum; Klaus H. Kaestner; Alexander C. Huang; Denitsa Hristova; Joshua Wang; Mizuho Fukunaga-Kalabis; Clemens Krepler; Fang Ping-Chen; Xiangyang Zhou; Alexis Gutierrez; Vito W. Rebecca; Prashanthi Vonteddu; Farokh Dotiwala; Shashi Bala; Sonali Majumdar; Harsh Dweep; Jayamanna Wickramasinghe; Andrew V. Kossenkov; Jorge Reyes-Arbujas; Kenisha Santiago; Tran Nguyen; Johannes Griss; Frederick Keeney; James Hayden; Brian J. Gavin; David Weiner; Luis J. Montaner; Qin Liu; Lukas Peiffer; Jürgen Becker; Elizabeth M. Burton; Michael A. Davies; Michael T. Tetzlaff; Kar Muthumani; Jennifer A. Wargo; Dmitry Gabrilovich; Meenhard Herlyn
Source
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Immune checkpoint therapies (ICT) are promising for treating various cancers, but response rates vary. Here the authors show, in mouse models, that tumor-infiltrating mast cells colocalize with regulatory T cells, coincide with local reduction of MHC-I and CD8 T cells, and is associated with resistance to ICT, which can be reversed by c-kit inhibitor treatment.